AI-CONECT: A Conversational AI for Early Dementia Prevention in Socially-Isolated Older Adults (AI-CONECT)
22 augusti 2026 uppdaterad av: Hiroko Hayama Dodge, Massachusetts General Hospital
AI-CONECT: A Conversational AI for Early Dementia Prevention in Socially-Isolated Older Adults Based on the Efficacy-Proven I-CONECT Study
This randomized controlled trial examines the mechanisms of conversational AI-based interventions for early dementia prevention in socially isolated older adults.
Studieöversikt
Status
Har inte rekryterat ännu
Intervention / Behandling
Detaljerad beskrivning
Social isolation is a well-established and modifiable risk factor for cognitive decline and dementia. The completed I-CONECT trial (NCT02871921) showed that frequent, one-to-one, semi-structured conversational engagement delivered remotely by trained human interviewers improved cognitive outcomes among socially isolated older adults with mild cognitive impairment. Two limitations have constrained translating that approach into a scalable preventive intervention: its reliance on trained human interviewers limits scalability, and the behavioral mechanisms responsible for its cognitive benefits remain incompletely understood.
AI-CONECT addresses both limitations by delivering the conversational intervention through a conversational artificial intelligence (AI) voice chatbot rather than a human interviewer, and by testing a hypothesized behavioral mechanism: that the intervention increases participants' social self-efficacy (confidence in their ability to engage socially), which in turn increases real-world social engagement.
Studietyp
Interventionell
Inskrivning (Beräknad)
80
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Catherine Young
- Telefonnummer: 617-724-2428
- E-post: cyoung@mgh.harvard.edu
Studieorter
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02129
- Massachusetts General Hospital
-
Kontakt:
- Catherine Young
- Telefonnummer: 617-724-2428
- E-post: cyoung@mgh.harvard.edu
-
Kontakt:
- Junyuan Hong, PhD
- Telefonnummer: 517-668-5790
- E-post: mr.junyuan.hong@gmail.com
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Aged 75+
- Clinical diagnosis of MCI (any subtype) or, when a clinical diagnosis is unavailable, a Telephone-MoCA (T-MoCA) score of 15-17.
- Identified as socially isolated, defined as meeting both of the following self-reported criteria: (a) lives alone in one's own residence, and (b) engages in conversations lasting 30 minutes or longer no more than twice per week.
- GDS-15 (15-item Geriatric Depression Scale) at/below 9 (not severely depressed).
- Social self-efficacy mean ≤ 8 (on the 0-10 scale) across the 6-item Social Self-Efficacy Scale at screening, indicating low confidence in social interaction.
- Ability to understand the research consent form.
- Ability to connect a tablet to the Internet.
Exclusion Criteria:
- Diagnosed with dementia such as AD, ischemic vascular dementia, normal pressure hydrocephalus, or Parkinson's disease.
- Schizophrenia, or other major psychiatric disorder defined by DSM-IV criteria.
- Medications: (a) Frequent use of high doses of analgesics; Use of sedative medications except for those used occasionally for sleep (≤2 per week); (b) Use of unstable dosing of Cholinesterase inhibitors (need to be stable dosing for 2 months); (c) AD disease modifying monoclonal antibody treatment e.g., aducanumab or lecanemab (completed the treatment is allowed)
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: AI-CONECT
Participants will receive four 15- to 30-minute conversations per week with the AI agent and a weekly 10- to15-minute survey call with a human interviewer.
|
AI-based one-on-one semi-structured conversation for cognitive stimulation
|
|
Inget ingripande: Control
Participants will receive a weekly 10- to 15-minute survey call with a human interviewer.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Social Self-Efficacy
Tidsram: From enrollment to the end of intervention at 8 weeks
|
Participants' self-efficacy on social interactions using an instrument adapted from the Exercise Self-Efficacy Scale (EXSE, by McAuley, 1993).
The scale comprises three items of confidence: interacting with others regularly, engaging with others when feeling less connected, and engaging others in conversations.
The three items are adapted to social interaction in person and using technology (e.g., video calls), respectively.
Each item is rated from 0 (not at all confident) to 10 (completely confident).
A mean score is computed across the six items (range 0-10), with higher scores indicating greater social self-efficacy.
|
From enrollment to the end of intervention at 8 weeks
|
|
Time contacting friends or family
Tidsram: From enrollment to the end of the intervention at 8 weeks, using weekly data
|
Change in weekly time contacting friends or family.
|
From enrollment to the end of the intervention at 8 weeks, using weekly data
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Time out of home
Tidsram: From enrollment to the end of treatment at 8 weeks
|
Self-reported weekly time out of home (a proximate measure of social engagement by the participants), using weekly data.
|
From enrollment to the end of treatment at 8 weeks
|
|
Frequency of contacting friends
Tidsram: From enrollment to the end of treatment at 8 weeks
|
Self-reported frequency of contacting friends, using weekly data.
|
From enrollment to the end of treatment at 8 weeks
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Exploratory outcome: Social isolation score
Tidsram: From baseline to week 8
|
Changes in Lubben's social isolation score (6-item version) from baseline to Week 8. The 6-item Lubben Social Network Scale (LSNS-6) is a brief measure of social isolation/social network size and support, particularly in older adults. It includes three questions about family ties and three about friendships, assessing the number of people the individual has contact with, feels close to, and can call on for help. Each item is scored from 0 to 5, giving a total score of 0-30. Higher scores indicate stronger social networks and less social isolation. |
From baseline to week 8
|
|
Exploratory outcome: Changes in the 3-item UCLA Loneliness Scale (UCLA-3)
Tidsram: From baseline to week 8
|
The 3-item UCLA Loneliness Scale (UCLA-3) is a brief measure of perceived loneliness and social disconnection.
It asks how often a person feels a lack of companionship, left out, and isolated from others.
Each item is scored from 1 (hardly ever) to 3 (often).
The total score ranges from 3 to 9, with higher scores indicating greater loneliness.
|
From baseline to week 8
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Hiroko H Dodge, PhD, Massachusetts General Hospital
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
1 oktober 2026
Primärt slutförande (Beräknad)
30 maj 2028
Avslutad studie (Beräknad)
30 september 2028
Studieregistreringsdatum
Först inskickad
19 februari 2026
Först inskickad som uppfyllde QC-kriterierna
13 juli 2026
Första postat (Faktisk)
14 juli 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
25 augusti 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
22 augusti 2026
Senast verifierad
1 augusti 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2026P000461
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
JA
IPD-planbeskrivning
De-identified transcriptions and other collected data may be shared with external researchers under a Data Use Agreement (DUA).
Shareable data may include outcome scores, adherence rates, chatbot-usage metrics, full conversational transcripts (after removal of any incidentally disclosed identifiable information), and audio recordings of sessions.
Because raw audio recordings may be inherently identifiable, they will be shared only under a DUA.
These data may also be made available to the NIH/NIA Program Official upon request.
Data are stored on HIPAA-compliant servers (e.g., MGB Business Dropbox and MGB Azure) and encrypted drives.
The participant linkage key is kept within Mass General Brigham.
No individual-level data are deposited in public or controlled-access repositories under the current protocol; future repository sharing would require additional IRB review and approval.
Tidsram för IPD-delning
De-identified data and related materials are available upon request; the current protocol does not specify a fixed availability start or end date.
Availability and retention follow Mass General Brigham and NIH record-retention requirements.
Kriterier för IPD Sharing Access
Requests are reviewed by the study team.
Sharing occurs only under an executed Data Use Agreement (DUA) or equivalent research agreement approved by the Mass General Brigham Contracting Office, is limited to de-identified (except audio recording as described above) or aggregated data for the analyses described in the protocol, and contractually prohibits re-identification and onward sharing.
Data are transferred only via Mass General Brigham-approved secure, encrypted methods.
IPD-delning som stöder informationstyp
- ANALYTIC_CODE
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .